Are you 18-75 years old? Do you have psoriasis? You may be able to participate in a study find out whether switching between ABP 501 (Amjevita®) and adalimumab (Humira®) treatments results in a similar effect on your psoriasis when compared with the use of adalimumab alone. Participation in this study will last up to 9 months. Compensation is provided.
IRB: SSU00165462- Amgen - 20200497 / 260859, A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared with Continued Use of Adalimumab in Subjects with Moderate to Severe Plaque (Pro00055441)
MEET THE RESEARCHER
Laura Korb Ferris, MD, PhD, is Associate Professor of Dermatology at the University of Pittsburgh School of Medicine, and is also the Director of Clinical Trials for the Department of Dermatology. Dr. Ferris earned her doctorate in immunology from Johns Hopkins University and her medical degree from the University of Maryland.